Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO
07:00am, Monday, 29'th Jul 2024
MINNEAPOLIS , July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds f
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
04:30pm, Wednesday, 17'th Jul 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS
07:00am, Monday, 15'th Jul 2024
MINNEAPOLIS , July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
09:30am, Friday, 21'st Jun 2024
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
HOLMDEL, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management and Identity-Bound Biometric solutions, will host
Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?
12:36pm, Thursday, 06'th Jun 2024
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Aptevo Participating in the BIO International Convention
08:05am, Monday, 03'rd Jun 2024
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprieta
Identity, Access Management Solutions Provider BIO-key to Participate in Fireside Chat at the Maxim Group Virtual Tech Conference, Tues. June 4th at 9am ET
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
07:00am, Friday, 31'st May 2024
MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor confer
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
09:55am, Thursday, 30'th May 2024
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
09:00am, Thursday, 30'th May 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt
Lineage to Present at 2024 BIO International Convention
08:00am, Thursday, 30'th May 2024
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell
Enveric Biosciences to Participate in BIO International Convention 2024
08:00am, Thursday, 30'th May 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE
07:00am, Thursday, 30'th May 2024
MINNEAPOLIS, May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass S
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
08:38am, Wednesday, 29'th May 2024
Corporate presentation scheduled for Monday, June 3, 2024 at 2:30 P.M. PDT CARMIEL, Israel , May 29, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical com
